Malaria Infections and Infestations
Conditions
Interventions
The study is a Phase 2 randomized controlled, partial-blind, parallel-group study in plasmodium infected asymptomatic adults 18 years and older, with 8 study arms. It will use the adapted Zelen design
Sponsors
Académie de recherche et d'enseignement supérieur
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Student or worker of a participating university 2. Aged 18 years and above, and in good general health condition 3. Have a device (phone, tablet, etc) that will support remote visits 4. Sign written informed consent form 5. Screened positive for malaria (RDT + and qPCR +) but asymptomatic
Exclusion criteria
Exclusion criteria: 1. Have a known hypersensitivity to any ingredients of the tea 2. Currently taking a malaria drug for prevention or treatment 3. Have participated in another malaria drug trial or device in the last 14 days 4. Have a history or presence of clinically significant medical, psychiatric, or emotional condition 5. Reported diabetic
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Parasite load measured using qPCR on blood samples collected at baseline, 7, 14, 28 and 35 days | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Gametocyte load measured using qPCR test on blood samples collected at baseline, 7, 14, 28 and 35 days 2. Acceptability (adherence and completion) of Artemisia afra treatment measured using participant interviews and observation of the number of days of compliance to treatment on the various treatment arms at baseline, 7, 14, 28 and 35 days 3. Safety (ASEs) of Artemisia afra treatment in participants measured using participant interviews and observation of the occurrence of any adverse events at 7, 14, 28, and 35 days | — |
Countries
Cameroon
Contacts
Public ContactSuh Nchang;Annie Abenwie;Robert
;
Outcome results
None listed